Hibbett Gets Price Target Cuts By Analysts After Weak Q1 Earnings

Hibbett, Inc. (NASDAQ: HIBB) reported worse-than-expected first-quarter results.

Hibbett, Inc. (NASDAQ:HIBB) reported worse-than-expected first-quarter results.

Hibbett reported first-quarter FY23 sales growth of 7.4% year-on-year to $455.50 million, missing the consensus of $460.40 million. EPS of $2.74 missed the analyst consensus of $3.04.

The company expects sales to be flat or rise by up to ~2.0% in dollars. Earlier, the company expected sales to be up mid-single digits.

Hibbett shares dropped 11.3% to close at $39.19 on Friday and added 0.3% in today’s pre-market trading session.

These analysts made changes to their price targets on Hibbett following earnings announcement.

  • Telsey Advisory Group cut the price target on Hibbett from $70 to $60. Telsey Advisory Group analyst Joseph Feldman maintained an Outperform rating.
  • Baird slashed the price target on Hibbett from $70 to $50. Baird analyst Peter Benedict maintained a Outperform rating.
  • Williams Trading, on Friday, lowered Hibbett price target from $54 to $37. Williams Trading analyst Sam Poser downgraded the stock from Hold to Sell.

 

Check This Out: This Analyst With 86% Accuracy Rate Sees Around 16% Upside In Nvidia – Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

Total
0
Shares
Related Posts
Read More

Why Allurion Technologies Stock Is Racing Higher

Allurion Technologies' Virtual Care Suite (VCS) is now available to license in the United States for providers offering GLP-1 and other anti-obesity medication therapy, bariatric surgery, and weight loss devices.  The company describes the VCS as a weight-loss management suite powered by artificial intelligence (AI) featuring remote patient monitoring, telehealth and care team collaboration. 

ALUR